The Disintegrins ADAM10 and TACE Contribute to the Constitutive and Phorbol Ester-regulated Normal Cleavage of the Cellular Prion Protein
We showed previously that PrPc undergoes constitutive and phorbol ester-regulated cleavage inside the 106–126 toxic domain of the protein, leading to the production of a fragment referred to as N1. Here we show by a pharmacological approach thato-phenanthroline, a general zinc-metalloprotease inhibi...
Gespeichert in:
Veröffentlicht in: | The Journal of biological chemistry 2001-10, Vol.276 (41), p.37743-37746 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We showed previously that PrPc undergoes constitutive and phorbol ester-regulated cleavage inside the 106–126 toxic domain of the protein, leading to the production of a fragment referred to as N1. Here we show by a pharmacological approach thato-phenanthroline, a general zinc-metalloprotease inhibitors, as well as BB3103 and TAPI, the inhibitors of metalloenzymes ADAM10 (Adisintegrinand metalloprotease); and TACE,tumor necrosis factorα-converting enzyme; ADAM17), respectively, drastically reduce N1 formation. We set up stable human embryonic kidney 293 transfectants overexpressing human ADAM10 and TACE, and we demonstrate that ADAM10 contributes to constitutive N1 production whereas TACE mainly participates in regulated N1 formation. Furthermore, constitutive N1 secretion is drastically reduced in fibroblasts deficient for ADAM10 whereas phorbol 12,13-dibutyrate-regulated N1 production is fully abolished in TACE-deficient cells. Altogether, our data demonstrate for the first time that disintegrins could participate in the catabolism of glycosyl phosphoinositide-anchored proteins such as PrPc. Second, our study identifies ADAM10 and ADAM17 as the protease candidates responsible for normal cleavage of PrPc. Therefore, these disintegrins could be seen as putative cellular targets of a therapeutic strategy aimed at increasing normal PrPcbreakdown and thereby depleting cells of the putative 106–126 “toxic” domain of PrPc. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M105677200 |